Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | GAPDH | P04406 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13269106 | 0.87 | ADORA1 (0.61) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL6905464 | 0.84 | ADORA1 (0.72) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL1434032 | 0.84 | ADORA1 (0.72) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL9341019 | 0.82 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL10997946 | 0.82 | ADORA1 (0.76) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL5024895 | 0.82 | ADORA1 (0.76) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL7803298 | 0.82 | ADORA1 (0.76) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL481524 | 0.82 | ADORA1 (0.76) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL12963362 | 0.82 | ADORA1 (0.76) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL2040670 | 0.82 | ADORA1 (0.76) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181498-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | EMERAMED LIMITED (IE) | 2023-06-15 | — | — | US | disclosed |
| US-11628151-B2 | N,N-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases | EMERAMED LIMITED (IE) | 2023-04-18 | — | — | US | disclosed |
| EP-4132501-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | EmeraMed Limited (IE) | 2023-02-15 | — | — | EP | disclosed |
| US-20230013704-A1 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | EMERAMED LTD (IE) | 2023-01-19 | — | — | US | disclosed |
| EP-4029497-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR TREATING OR PREVENTING PARACETAMOL TOXICITY | EmeraMed Limited (IE) | 2022-07-20 | — | — | EP | disclosed |
| EP-3493849-B1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | EMERAMED LTD (IE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3903774-A1 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | EmeraMed Limited (IE) | 2021-11-03 | — | — | EP | disclosed |
| US-20190240173-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | EMERAMED LIMITED (IE) | 2019-08-08 | — | — | US | disclosed |
| US-20180250247-A1 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | EMERAMED LTD (IE) | 2018-09-06 | — | — | US | disclosed |
| EP-3125876-B1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | EMERAMED LTD (IE) | 2017-11-29 | — | — | EP | disclosed |
| US-9782368-B2 | Use of N,N-bis-2-mercaptoethyl isophthalamide | EMERAMED LIMITED (IE) | 2017-10-10 | — | — | US | disclosed |
| US-20170202791-A1 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | EMERAMED LIMITED (IE) | 2017-07-20 | — | — | US | disclosed |
| US-20170157072-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | EMERAMED LIMITED (IE) | 2017-06-08 | — | — | US | disclosed |
| EP-3148588-A1 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Emeramed Limited (IE) | 2017-04-05 | — | — | EP | disclosed |
| EP-3125876-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | Emeramed Limited (IE) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015181567-A1 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ERMES MEDICAL COMPANY LIMITED (IE) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015150793-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | ERMES MEDICAL COMPANY LTD (IE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240173-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | NNMT, NPM1, SLC10A1 | ADORA1 3047/4885ADORA3 2672/4885ADORA2A 1914/4885 |
| US-20230181498-A1 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE | MME, NNMT, NPM1 | ADORA1 2861/4885ADORA3 2492/4885ADORA2A 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.